M. J. Ramalho, S. Andrade, J. A. Loureiro, and M. do Carmo Pereira, “Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds,” Drug Delivery and Translational Research. 2020, doi: 10.1007/s13346-019-00694-3.
 R. H. Muller, R. Shegokar, and C. M. Keck, “20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications,” Curr. Drug Discov. Technol., 2011, doi: 10.2174/157016311796799062.
 A. J. Almeida and E. Souto, “Solid lipid nanoparticles as a drug delivery system for peptides and proteins,” Advanced Drug Delivery Reviews. 2007, doi: 10.1016/j.addr.2007.04.007.
 T. Alam, M. A. Ansari, S. Baboota, and J. Ali, “Nanostructured lipid carriers of isradipine for effective management of hypertension and isoproterenol induced myocardial infarction,” Drug Deliv. Transl. Res., 2021, doi: 10.1007/s13346-021-00958-x.
 M. T. Pineda-Hernández, J. T. Pérez-Urizar, and A. Ganem-Rondero, “Thermo-reversible in situ forming implant with nanostructured lipid carriers (NLC) as a delivery system for the administration of estradiol valerate,” Drug Deliv. Transl. Res., 2020, doi: 10.1007/s13346-019-00704-4.
 A. Mahmood, V. K. Rapalli, S. Gorantla, T. Waghule, and G. Singhvi, “Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations,” Drug Deliv. Transl. Res., 2021, doi: 10.1007/s13346-021-00986-7.
 S. Wiemann and C. M. Keck, “Are lipid nanoparticles really superior? A holistic proof of concept study.,” Drug Deliv. Transl. Res., Sep. 2021, doi: 10.1007/s13346-021-01021-5.
 P. O. Nnamani et al., “Formulation and evaluation of transdermal nanogel for delivery of artemether,” Drug Deliv. Transl. Res., 2021, doi: 10.1007/s13346-021-00951-4.
 A. Gryczke, S. Schminke, M. Maniruzzaman, J. Beck, and D. Douroumis, “Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion.,” Colloids Surf. B. Biointerfaces, vol. 86, no. 2, pp. 275–284, Sep. 2011, doi: 10.1016/j.colsurfb.2011.04.007.
 C. N. Nguyen, T. T. T. Nguyen, H. T. Nguyen, and T. H. Tran, “Nanostructured lipid carriers to enhance transdermal delivery and efficacy of diclofenac,” Drug Deliv. Transl. Res., 2017, doi: 10.1007/s13346-017-0415-2.
 J. S. R. Viegas et al., “Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis,” Drug Deliv. Transl. Res., 2020, doi: 10.1007/s13346-020-00723-6.
 F. Meng et al., “A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer’s disease,” Colloids Surfaces B Biointerfaces, 2015, doi: 10.1016/j.colsurfb.2015.06.025.
 V. C. Gurumukhi and S. B. Bari, “Quality by design (QbD)–based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies,” Drug Deliv. Transl. Res., 2021, doi: 10.1007/s13346-021-01014-4.
 S. Rawal, B. Patel, and M. M. Patel, “Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-loaded nanostructured lipid carriers for improved antitumor activity against non-small cell lung carcinoma,” J. Microencapsul., 2020, doi: 10.1080/02652048.2020.1823498.
 P. Mathur, S. Sharma, S. Rawal, B. Patel, and M. M. Patel, “Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity,” J. Liposome Res., 2020, doi: 10.1080/08982104.2019.1614055.
 L. Yang et al., “The effect of curcumin on proliferation and apoptosis in LNCaP prostate cancer cells,” Chinese J. Clin. Oncol., 2006, doi: 10.1007/s11805-006-0072-6.
 C. Puglia et al., “Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice,” Eur. J. Pharm. Biopharm., 2012, doi: 10.1016/j.ejpb.2012.03.015.
 A. P. Nayak, W. Tiyaboonchai, S. Patankar, B. Madhusudhan, and E. B. Souto, “Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment,” Colloids Surfaces B Biointerfaces, 2010, doi: 10.1016/j.colsurfb.2010.07.020.
 M. Fang et al., “In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration,” Int. J. Nanomedicine, 2012, doi: 10.2147/IJN.S36257.
 V. Kakkar, S. Singh, D. Singla, and I. P. Kaur, “Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin,” Mol. Nutr. Food Res., 2011, doi: 10.1002/mnfr.201000310.
 F. Castelli, C. Puglia, M. G. Sarpietro, L. Rizza, and F. Bonina, “Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry,” Int. J. Pharm., 2005, doi: 10.1016/j.ijpharm.2005.08.011.
 J. Liu, S. Chen, L. Lv, L. Song, S. Guo, and S. Huang, “Recent Progress in Studying Curcumin and its Nano-preparations for Cancer Therapy,” Curr. Pharm. Des., 2013, doi: 10.2174/1381612811319110003.
 R. S. Mulik, J. Mönkkönen, R. O. Juvonen, K. R. Mahadik, and A. R. Paradkar, “Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anticancer activity by induction of apoptosis,” Int. J. Pharm., 2010, doi: 10.1016/j.ijpharm.2010.07.021.
 T. Suzuki, K. Fujikura, T. Higashiyama, and K. Takata, “DNA staining for fluorescence and laser confocal microscopy.,” J. Histochem. Cytochem. Off. J. Histochem. Soc., vol. 45, no. 1, pp. 49–53, Jan. 1997, doi: 10.1177/002215549704500107.
 P. A. J. Speth, Q. G. C. M. van Hoesel, and C. Haanen, “Clinical Pharmacokinetics of Doxorubicin,” Clinical Pharmacokinetics. 1988, doi: 10.2165/00003088-198815010-00002.
 M. T. Huang, R. C. Smart, C. Q. Wong, and A. H. Conney, “Inhibitory Effect of Curcumin, Chlorogenic Acid, Caffeic Acid, and Ferulic Acid on Tumor Promotion in Mouse Skin by 12-O-Tetradecanoylphorbol-13-Acetate,” Cancer Res., 1988.
 T. C. Hour, J. Chen, C. Y. Huang, J. Y. Guan, S. H. Lu, and Y. S. Pu, “Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIP1 and C/EBPβ expressions and suppressing NF-κB activation,” Prostate, 2002, doi: 10.1002/pros.10089.
 R. G. Madane and H. S. Mahajan, “Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study,” Drug Deliv., 2016, doi: 10.3109/10717544.2014.975382.
 J. Duan et al., “Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles,” Int. J. Pharm., 2010, doi: 10.1016/j.ijpharm.2010.08.033.
 Y. Chen, Q. Wu, Z. Zhang, L. Yuan, X. Liu, and L. Zhou, “Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics,” Molecules, 2012, doi: 10.3390/molecules17055972.